Bupropion is not classified as a controlled substance in the United States [1]. It is available by prescription and is used to treat major depressive disorder and seasonal affective disorder [2].
How does bupropion work?
Bupropion is thought to work by affecting the levels of certain neurotransmitters in the brain, primarily norepinephrine and dopamine [2]. It is an aminoketone antidepressant, distinguishing it from other classes of antidepressants that primarily target serotonin [2][3].
What are the side effects of bupropion?
Common side effects of bupropion can include dry mouth, insomnia, nausea, headache, dizziness, and tremor [4]. Less common but more serious side effects may include seizures, high blood pressure, and allergic reactions [4].
When does bupropion patent exclusivity expire?
Information regarding specific patent expiry dates for bupropion and its formulations is available on DrugPatentWatch.com [5].
Are there other medications for depression?
Yes, there are several other classes of medications used to treat depression, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [3]. Bupropion differs in its mechanism of action and side effect profile compared to these other classes [3].
Can bupropion be prescribed for other conditions?
Bupropion is also available in combination with naltrexone for weight management under the brand name Contrave [6]. It has also been investigated for other uses, such as smoking cessation, though other medications are more commonly prescribed for this purpose [7].
Sources:
1. U.S. Food & Drug Administration. (n.d.). Controlled Substances Act.
2. National Alliance on Mental Illness. (n.d.). Bupropion.
3. American Psychiatric Association. (n.d.). Practice Guideline for the Pharmacological Treatment of Patients With Depression in Primary Care.
4. Mayo Clinic. (n.d.). Bupropion (Oral Route).
5. DrugPatentWatch.com. (n.d.). Bupropion Patents.
6. U.S. Food & Drug Administration. (n.d.). FDA Approves New Drug Combination for Chronic Weight Management.
7. U.S. Food & Drug Administration. (n.d.). Smoking Cessation Products.